By Marcello Cherchi, MD PhD
For patients
In postural orthostatic tachycardia syndrome (POTS), going from a lying down position to a seated or standing position causes the heart rate to increase too much, and a patient may notice palpitations, trouble breathing, feeling faint, or actually fainting (in the sense of losing consciousness). POTS can be caused by several problems. If your doctor suspects POTS, then they may check several tests. Depending on the underlying cause of POTS, it may be treated without or with medications.
For clinicians
Overview
In simple terms, postural orthostatic tachycardia syndrome (POTS) is a type of orthostatic intolerance in which going from a supine/prone position to an upright (standing more than seated) position provokes an inappropriately large increase in heart rate, associated with symptoms such as palpitations, lightheadedness, shortness of breath, presyncope or syncope. The age of onset of POTS ranges from 12 – 50 years, and is more common in women by a factor of 4:1. POTS can occur in apparent isolation, but is often the consequence of some other problem (e.g., medications, volume depletion). POTS can often be identified on physical examination; some cases may require confirmation on tilt table testing. Treatment depends on the underlying cause (if discernible), and can include pharmacologic and non-pharmacologic strategies.
Introduction
Postural orthostatic tachycardia syndrome (POTS) is a type of orthostatic intolerance in which going from a supine/prone position to an upright (standing more than seated) position provokes an inappropriately large increase in heart rate, associated with symptoms such as palpitations, lightheadedness, shortness of breath, presyncope or syncope.
Epidemiology
Vernio and colleagues (Vernino et al. 2021), citing several other studies (Arnold et al. 2018; Low et al. 2009; Sheldon et al. 2015), states that estimates of the prevalence of POTS in the United States range from 0.2% – 1%, with a typical age range of 12 – 50 years and a female to male ratio greater than 4:1.
Genetics
Postural orthostatic tachycardia (POTS) in itself is not known to have a specific genetic mechanism (Qu et al. 2025). However, there are some genetically transmitted diseases, such as some forms of Ehlers-Danlos syndrome, whose manifestations can include POTS.
Pathophysiological mechanism of disease
Robbins and colleagues summarize:
“The core symptoms of POTS are related to low central blood volume. Decreased venous return to the heart results in decreased stroke volume and is accompanied by sympathetic activation and increase[d] heart rate, presumably to maintain cardiac output and perfusion. Symptoms result from either low cerebral perfusion (e.g., lightheadedness/presyncope) or excess sympathetic activity (e.g., tachycardia, palpitations, jitteriness). Hyperpnea is also seen as are other symptoms such as brain fog and paresthesia” (Robbins et al. 2026).
In addition:
“Patients with POTS often worsen with factors that lower cerebral perfusion and systemic blood pressure (BP), such as elevated temperature (because of heat-induced cutaneous vasodilation), volume depletion, vasodilatory substances (such as alcohol or medications), large meals (when blood is shunted to the splanchnic circulation and vasoactive gut peptides are released), and prolonged standing (with gravitational blood pooling)” (Robbins et al. 2026).
Numerous medications from several classes can cause or exacerbate POTS, including diuretics, some antihypertensive agents, anticholinergics, tricyclic compounds, SSRIs, SNRIs, bupropion and amphetamine derivatives (Robbins et al. 2026).
It is likely that many cases of POTS have more than one underlying mechanism or predisposing factor, as suggested in the Figure 1 below from Arnold and colleagues (Arnold et al. 2018).
Figure : Schematic diagram of multiple potential pathophysiologic processes in POTS. Abbreviations: NE=norepinephrine; NET=norepinephrine transporter; NETi=norepinephrine transporter inhibitor; SNRI=selective norepinephrine reuptake inhibitor; SNS=sympathetic nervous system. From Arnold et al (Arnold et al. 2018).
Clinical presentation
Robbins and colleagues state that “Orthostatic intolerance is typically the core clinical complaint, manifesting as racing heart, lightheadedness/presyncope, dyspnea, palpitations, and other symptoms brought on by upright position” (Robbins et al. 2026).
Physical examination
Consensus criteria usually define POTS as an increase in heart rate of ≥30 beats per minute within 10 minutes of going from a supine to a standing position (Freeman et al. 2011; Raj et al. 2020; Sheldon et al. 2015).
Robbins and colleagues (Robbins et al. 2026) summarize:
“Orthostatic vital signs are best measured with an active stand test. BP and HR should be measured in a supine patient after the patient rests quietly for at least 5–10 minutes, and then again periodically after immediately standing (without sitting in between) for at least 5 minutes, and ideally for 10 minutes (Raj et al. 2020). Some patients who do not meet the threshold for excessive orthostatic tachycardia with active standing could have greater HR augmentation with tilt table testing (Uppal et al. 2025)” (Robbins et al. 2026).
Ocular motor examination
Ocular motor examination does not help to confirm or exclude POTS, but may be useful in excluding competing diagnoses.
Testing: auditory
Auditory testing does not help to confirm or exclude POTS, but may be useful in excluding competing diagnoses.
Testing: vestibular
Emerging evidence suggests that disorders of otolithic function may contribute to postural orthostatic tachycardia (Kim et al. 2023; Woo et al. 2026), though tests of otolithic function in themselves neither confirm nor refute a diagnosis of POTS.
The main role of vestibular testing in patients with confirmed or suspected POTS is to exclude competing diagnoses.
Testing: other
Tilt table testing (TTT) can be helpful in securing a diagnosis of POTS, particularly in patients in whom there is a longer latency between the positional changes (standing up) and onset of symptoms (Uppal et al. 2025).
Imaging
Neuroimaging does not help confirm or exclude a diagnosis of POTS.
Differential diagnosis
The differential diagnosis of POTS includes the other categories or orthostatic intolerance (orthostatic hypotension, orthostatic hypertension), as well as other diseases that can cause positionally-triggered disequilibrium, such as benign paroxysmal positional vertigo (BPPV).
Management
Non-pharmacologic and pharmacologic treatments have been studied in the management of POTS.
Non-pharmacologic strategies reviewed by Robbins and colleagues (Robbins et al. 2026) include:
- Graded cardiovascular exercise (Bryarly et al. 2019; Fu and Levine 2018; George et al. 2016; Gibbons et al. 2021; Wheatley-Guy et al. 2023; Ziaks et al. 2024).
- Increased hydration (Snapper and Cheshire 2022).
- Liberalizing dietary sodium intake (Garland et al. 2021).
- Compression garments (Bourne et al. 2021).
- Physical counterpressure maneuvers to manage acute episodes (van Dijk et al. 2006).
Pharmacologic strategies reviewed by Robbins and colleagues (Robbins et al. 2026) include:
- Midodrine 2.5 – 10 mg in the morning and mid-day, sometimes in the evening (but the latter entails the risk of supine hypertension) (Chen et al. 2011; Ross et al. 2014).
- Beta blockers with CNS penetration, such as propranolol 10 – 20 mg one to three times per day (Raj 2013). This can be particularly useful for palpitations, tachycardia and anxiety.
- Pyridostigmine 30 – 60 mg three times per day (L et al. 2020) may be useful for tachycardia.
- Fludrocortisone 0.1 – 0.2 mg per day can be helpful in patients with hypovolemia and syncope/presyncope.
- Ivabradine 5 mg twice per day (Cappato et al. 2012) can be helpful for palpitations.
- Guanfacine 1 mg once per night (Okamoto et al. 2024) can be helpful for tachycardia.
- Intravenous normal saline 1 – 2 liters (Snapper and Cheshire 2022) as needed when patients present to an emergency room for symptoms related to volume depletion.
Prognosis
Limited data regarding prognosis of POTS are reviewed by Arnold and colleagues (Arnold et al. 2018), and suggest significant variability.
- A prospective study of 58 adults (49 females, 84%) reported that at 12 months of follow-up there was symptomatic improvement in “most patients,” and 37% of patients no longer met criteria for POTS (Kimpinski et al. 2012).
- A retrospective questionnaire-based study of 47 adolescents treated with either midodrine or beta blockers concluded that, “Treatment with both midodrine and beta-blockers was associated with overall improvement in POTS patients’ general health; however, adolescents taking beta-blockers were more likely than those taking midodrine to credit the role of medications in their improvement” (Lai et al. 2009).
- A retrospective review identified 34 patients (88% women) with a median age of 24 years. Sixteen of these patients were followed-up at 92 ± 41 months; they had implemented some combination of lifestyle modifications (hydration, sodium intake), physical counterpressure maneuvers, compression garments, and medications (bisoprolol, fludrocortisone, midodrine, SSRIs). Of these 16 patients, “five patients were completely asymptomatic, nine reported significant improvement, and only two remained highly symptomatic” (Sousa et al. 2012).
- A questionnaire-based survey of 172 patients diagnosed with POTS in adolescence reported that 33 (19%) experienced complete symptom resolution, 87 (51%) described persistent but improved symptoms, and 28 (16%) had only intermittent symptoms (Bhatia et al. 2016).
References
Arnold AC, Ng J, Raj SR (2018) Postural tachycardia syndrome – Diagnosis, physiology, and prognosis. Auton Neurosci 215: 3-11. doi: 10.1016/j.autneu.2018.02.005
Bhatia R, Kizilbash SJ, Ahrens SP, Killian JM, Kimmes SA, Knoebel EE, Muppa P, Weaver AL, Fischer PR (2016) Outcomes of Adolescent-Onset Postural Orthostatic Tachycardia Syndrome. J Pediatr 173: 149-53. doi: 10.1016/j.jpeds.2016.02.035
Bourne KM, Sheldon RS, Hall J, Lloyd M, Kogut K, Sheikh N, Jorge J, Ng J, Exner DV, Tyberg JV, Raj SR (2021) Compression Garment Reduces Orthostatic Tachycardia and Symptoms in Patients With Postural Orthostatic Tachycardia Syndrome. J Am Coll Cardiol 77: 285-296. doi: 10.1016/j.jacc.2020.11.040
Bryarly M, Phillips LT, Fu Q, Vernino S, Levine BD (2019) Postural Orthostatic Tachycardia Syndrome: JACC Focus Seminar. J Am Coll Cardiol 73: 1207-1228. doi: 10.1016/j.jacc.2018.11.059
Cappato R, Castelvecchio S, Ricci C, Bianco E, Vitali-Serdoz L, Gnecchi-Ruscone T, Pittalis M, De Ambroggi L, Baruscotti M, Gaeta M, Furlanello F, Di Francesco D, Lupo PP (2012) Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol 60: 1323-9. doi: 10.1016/j.jacc.2012.06.031
Chen L, Wang L, Sun J, Qin J, Tang C, Jin H, Du J (2011) Midodrine hydrochloride is effective in the treatment of children with postural orthostatic tachycardia syndrome. Circ J 75: 927-31. doi: 10.1253/circj.cj-10-0514
Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, Cheshire WP, Chelimsky T, Cortelli P, Gibbons CH, Goldstein DS, Hainsworth R, Hilz MJ, Jacob G, Kaufmann H, Jordan J, Lipsitz LA, Levine BD, Low PA, Mathias C, Raj SR, Robertson D, Sandroni P, Schatz IJ, Schondorf R, Stewart JM, van Dijk JG (2011) Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci 161: 46-8. doi: 10.1016/j.autneu.2011.02.004
Fu Q, Levine BD (2018) Exercise and non-pharmacological treatment of POTS. Auton Neurosci 215: 20-27. doi: 10.1016/j.autneu.2018.07.001
Garland EM, Gamboa A, Nwazue VC, Celedonio JE, Paranjape SY, Black BK, Okamoto LE, Shibao CA, Biaggioni I, Robertson D, Diedrich A, Dupont WD, Raj SR (2021) Effect of High Dietary Sodium Intake in Patients With Postural Tachycardia Syndrome. J Am Coll Cardiol 77: 2174-2184. doi: 10.1016/j.jacc.2021.03.005
George SA, Bivens TB, Howden EJ, Saleem Y, Galbreath MM, Hendrickson D, Fu Q, Levine BD (2016) The international POTS registry: Evaluating the efficacy of an exercise training intervention in a community setting. Heart Rhythm 13: 943-50. doi: 10.1016/j.hrthm.2015.12.012
Gibbons CH, Silva G, Freeman R (2021) Cardiovascular exercise as a treatment of postural orthostatic tachycardia syndrome: A pragmatic treatment trial. Heart Rhythm 18: 1361-1368. doi: 10.1016/j.hrthm.2021.01.017
Kim KT, Lee SU, Kim JB, Choi JY, Kim BJ, Kim JS (2023) Augmented ocular vestibular-evoked myogenic potentials in postural orthostatic tachycardia syndrome. Clin Auton Res 33: 479-489. doi: 10.1007/s10286-023-00943-z
Kimpinski K, Figueroa JJ, Singer W, Sletten DM, Iodice V, Sandroni P, Fischer PR, Opfer-Gehrking TL, Gehrking JA, Low PA (2012) A prospective, 1-year follow-up study of postural tachycardia syndrome. Mayo Clin Proc 87: 746-52. doi: 10.1016/j.mayocp.2012.02.020
L YL, D SC, R KS, R SS, S RR (2020) Non-Pharmacological and Pharmacological Management of Cardiac Dysautonomia Syndromes. J Atr Fibrillation 13: 2395. doi: 10.4022/jafib.2395
Lai CC, Fischer PR, Brands CK, Fisher JL, Porter CB, Driscoll SW, Graner KK (2009) Outcomes in adolescents with postural orthostatic tachycardia syndrome treated with midodrine and beta-blockers. Pacing Clin Electrophysiol 32: 234-8. doi: 10.1111/j.1540-8159.2008.02207.x
Low PA, Sandroni P, Joyner M, Shen WK (2009) Postural tachycardia syndrome (POTS). J Cardiovasc Electrophysiol 20: 352-8. doi: 10.1111/j.1540-8167.2008.01407.x
Okamoto LE, Urechie V, Rigo S, Abner JJ, Giesecke M, Muldowney JAS, Furlan R, Shibao CA, Shirey-Rice JK, Pulley JM, Diedrich A, Biaggioni I (2024) Hyperadrenergic Postural Tachycardia Syndrome: Clinical Biomarkers and Response to Guanfacine. Hypertension 81: 2237-2247. doi: 10.1161/HYPERTENSIONAHA.124.23035
Qu H, Qu J, Chang X, Williams N, Mentch F, Snyder J, Lemma M, Nguyen K, Behr M, March M, Connolly J, Glessner J, Boris JR, Hakonarson H (2025) The genetic landscape of pediatric postural orthostatic tachycardia syndrome. Clin Auton Res 35: 431-451. doi: 10.1007/s10286-025-01110-2
Raj SR (2013) Postural tachycardia syndrome (POTS). Circulation 127: 2336-42. doi: 10.1161/CIRCULATIONAHA.112.144501
Raj SR, Guzman JC, Harvey P, Richer L, Schondorf R, Seifer C, Thibodeau-Jarry N, Sheldon RS (2020) Canadian Cardiovascular Society Position Statement on Postural Orthostatic Tachycardia Syndrome (POTS) and Related Disorders of Chronic Orthostatic Intolerance. Can J Cardiol 36: 357-372. doi: 10.1016/j.cjca.2019.12.024
Robbins NM, Golden EP, Freeman KC, Bhavaraju-Sanka RK, Snapper H, Cook GA (2026) Approach to Postural Orthostatic Tachycardia Syndrome. Neurol Clin Pract 16: e200620. doi: 10.1212/CPJ.0000000000200620
Ross AJ, Ocon AJ, Medow MS, Stewart JM (2014) A double-blind placebo-controlled cross-over study of the vascular effects of midodrine in neuropathic compared with hyperadrenergic postural tachycardia syndrome. Clin Sci (Lond) 126: 289-96. doi: 10.1042/CS20130222
Sheldon RS, Grubb BP, 2nd, Olshansky B, Shen WK, Calkins H, Brignole M, Raj SR, Krahn AD, Morillo CA, Stewart JM, Sutton R, Sandroni P, Friday KJ, Hachul DT, Cohen MI, Lau DH, Mayuga KA, Moak JP, Sandhu RK, Kanjwal K (2015) 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm 12: e41-63. doi: 10.1016/j.hrthm.2015.03.029
Snapper H, Cheshire WP (2022) Oral and intravenous hydration in the treatment of orthostatic hypotension and postural tachycardia syndrome. Auton Neurosci 238: 102951. doi: 10.1016/j.autneu.2022.102951
Sousa A, Lebreiro A, Freitas J, Maciel MJ (2012) Long-term follow-up of patients with postural tachycardia syndrome. Clin Auton Res 22: 151-3. doi: 10.1007/s10286-011-0155-1
Uppal J, Baker JR, Hira R, Karalasingham K, Ranada S, Deol P, Sheldon RS, Raj SR (2025) Physiological and clinical comparison of active stand and head-up tilt tests in Postural Orthostatic Tachycardia Syndrome (POTS). Auton Neurosci 260: 103281. doi: 10.1016/j.autneu.2025.103281
van Dijk N, Quartieri F, Blanc JJ, Garcia-Civera R, Brignole M, Moya A, Wieling W, Investigators PC-T (2006) Effectiveness of physical counterpressure maneuvers in preventing vasovagal syncope: the Physical Counterpressure Manoeuvres Trial (PC-Trial). J Am Coll Cardiol 48: 1652-7. doi: 10.1016/j.jacc.2006.06.059
Vernino S, Bourne KM, Stiles LE, Grubb BP, Fedorowski A, Stewart JM, Arnold AC, Pace LA, Axelsson J, Boris JR, Moak JP, Goodman BP, Chemali KR, Chung TH, Goldstein DS, Diedrich A, Miglis MG, Cortez MM, Miller AJ, Freeman R, Biaggioni I, Rowe PC, Sheldon RS, Shibao CA, Systrom DM, Cook GA, Doherty TA, Abdallah HI, Darbari A, Raj SR (2021) Postural orthostatic tachycardia syndrome (POTS): State of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting – Part 1. Auton Neurosci 235: 102828. doi: 10.1016/j.autneu.2021.102828
Wheatley-Guy CM, Shea MG, Parks JK, Scales R, Goodman BP, Butterfield RJ, Johnson BD (2023) Semi-supervised exercise training program more effective for individuals with postural orthostatic tachycardia syndrome in randomized controlled trial. Clin Auton Res 33: 659-672. doi: 10.1007/s10286-023-00970-w
Woo T, Kim Y, Kim J, Park JW, Lee SU, Park E, Kim GJ, Kim BJ, Kim JS (2026) Vestibulo-sympathetic interaction and otolith function in postural orthostatic tachycardia syndrome. Clin Auton Res 36: 89-101. doi: 10.1007/s10286-025-01163-3
Ziaks L, Johnson K, Schiltz K, Pelo R, Lamotte G, Dal Molin C, Chung T, Cortez MM (2024) Adaptive Approaches to Exercise Rehabilitation for Postural Tachycardia Syndrome and Related Autonomic Disorders. Arch Rehabil Res Clin Transl 6: 100366. doi: 10.1016/j.arrct.2024.100366
